Arteriosclerosis, Vol 10, 1067-1073, Copyright © 1990 by American Heart Association

ARTICLES

Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein

A Stiko-Rahm, B Wiman, A Hamsten and J Nilsson
King Gustaf V Research Institute, Karolinska Hospital, Stockholm, Sweden.

Clinical studies have demonstrated an impaired fibrinolytic function in patients with angiographically ascertained coronary artery disease or previous myocardial infarction. This decreased fibrinolytic function is to a major extent explained by the presence of high plasma levels of plasminogen activator inhibitor-1 (PAI-1) and is most common in patients with hyperlipoproteinemias type IIB and IV. To further investigate the association between hypertriglyceridemia and elevated plasma levels of PAI-1, cultured human umbilical vein endothelial cells were exposed to purified lipoproteins isolated from normo- and hypertriglyceridemic (NTG and HTG) individuals. We found that very low density lipoprotein (VLDL) from both NTG and HTG subjects stimulated the secretion of PAI-1 from endothelial cells in a dose-dependent manner. HTG-VLDL at a concentration of 100 micrograms/ml gave rise to a 73% increase in PAI-1 secretion as compared to control cultures, whereas NTG-VLDL only gave rise to a 30% increase (p less than 0.05), indicating that HTG-VLDL is a more potent stimulus to PAI-1 secretion than is NTG-VLDL. Experiments in which endothelial cells were exposed to VLDL subfractions indicated that large VLDL particles, in particular, induce PAI-1 release. Binding experiments demonstrated a specific cellular binding of both NTG- and HTG-VLDL to the cells, but HTG-VLDL bound about four times more effectively than NTG-VLDL. Exposure of the endothelial cells to an LDL receptor antibody was found to block 75% (p less than 0.005) of the VLDL-induced secretion of PAI-1 from the cells.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				M.-C. Alessi and I. Juhan-Vague PAI-1 and the Metabolic Syndrome: Links, Causes, and Consequences Arterioscler. Thromb. Vasc. Biol., October 1, 2006; 26(10): 2200 - 2207. [Abstract] [Full Text] [PDF]

				E. M Hjerkinn, I. Seljeflot, I. Ellingsen, P. Berstad, I. Hjermann, L. Sandvik, and H. Arnesen Influence of long-term intervention with dietary counseling, long-chain n-3 fatty acid supplements, or both on circulating markers of endothelial activation in men with long-standing hyperlipidemia Am. J. Clinical Nutrition, March 1, 2005; 81(3): 583 - 589. [Abstract] [Full Text] [PDF]

				T. J. Lyons, A. J. Jenkins, D. Zheng, D. T. Lackland, D. McGee, W. T. Garvey, and R. L. Klein Diabetic Retinopathy and Serum Lipoprotein Subclasses in the DCCT/EDIC Cohort Invest. Ophthalmol. Vis. Sci., March 1, 2004; 45(3): 910 - 918. [Abstract] [Full Text] [PDF]

				G.D. Norata, A. Pirillo, E. Callegari, A. Hamsten, A.L. Catapano, and P. Eriksson Gene expression and intracellular pathways involved in endothelial dysfunction induced by VLDL and oxidised VLDL Cardiovasc Res, July 1, 2003; 59(1): 169 - 180. [Abstract] [Full Text] [PDF]

				M. G. Modena, L. Bonetti, F. Coppi, F. Bursi, and R. Rossi Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women J. Am. Coll. Cardiol., August 7, 2002; 40(3): 505 - 510. [Abstract] [Full Text] [PDF]

				D. M. Herrington and K. P. Klein Genome and Hormones: Gender Differences in Physiology: Invited Review: Pharmacogenetics of estrogen replacement therapy J Appl Physiol, December 1, 2001; 91(6): 2776 - 2784. [Abstract] [Full Text] [PDF]

				J. M. Bard, M. A. Charles, I. Juhan-Vague, P. Vague, P. Andre, M. Safar, J. C. Fruchart, E. Eschwege, and o. b. o. t. BIGPRO Study Group Accumulation of Triglyceride-Rich Lipoprotein in Subjects With Abdominal Obesity : The Biguanides and the Prevention of the Risk of Obesity (BIGPRO) 1 Study Arterioscler. Thromb. Vasc. Biol., March 1, 2001; 21(3): 407 - 414. [Abstract] [Full Text] [PDF]

				P. A. Sakkinen, P. Wahl, M. Cushman, M. R. Lewis, and R. P. Tracy Clustering of Procoagulation, Inflammation, and Fibrinolysis Variables with Metabolic Factors in Insulin Resistance Syndrome Am. J. Epidemiol., November 15, 2000; 152(10): 897 - 907. [Abstract] [Full Text] [PDF]

				E. M. Tabengwa, R. L. Benza, H. E. Grenett, and F. M. Booyse Hypertriglyceridemic VLDL Downregulates Tissue Plasminogen Activator Gene Transcription Through cis-Repressive Region(s) in the Tissue Plasminogen Activator Promoter in Cultured Human Endothelial Cells Arterioscler. Thromb. Vasc. Biol., June 1, 2000; 20(6): 1675 - 1681. [Abstract] [Full Text] [PDF]

				S. Ren and G. X. Shen Impact of Antioxidants and HDL on Glycated LDL-Induced Generation of Fibrinolytic Regulators From Vascular Endothelial Cells Arterioscler. Thromb. Vasc. Biol., June 1, 2000; 20(6): 1688 - 1693. [Abstract] [Full Text] [PDF]

				K. P. Rentrop Thrombi in Acute Coronary Syndromes : Revisited and Revised Circulation, April 4, 2000; 101(13): 1619 - 1626. [Full Text] [PDF]

				S. Ren, S. Shatadal, and G. X. Shen Protein kinase C-beta mediates lipoprotein-induced generation of PAI-1 from vascular endothelial cells Am J Physiol Endocrinol Metab, April 1, 2000; 278(4): E656 - E662. [Abstract] [Full Text] [PDF]

				K. A. Poli, G. H. Tofler, M. G. Larson, J. C. Evans, P. A. Sutherland, I. Lipinska, M. A. Mittleman, J. E. Muller, R. B. D’Agostino, P. W. F. Wilson, et al. Association of Blood Pressure With Fibrinolytic Potential in the Framingham Offspring Population Circulation, January 25, 2000; 101(3): 264 - 269. [Abstract] [Full Text] [PDF]

				W. Dichtl, A. Stiko, P. Eriksson, I. Goncalves, F. Calara, C. Banfi, M. P. S. Ares, A. Hamsten, and J. Nilsson Oxidized LDL and Lysophosphatidylcholine Stimulate Plasminogen Activator Inhibitor-1 Expression in Vascular Smooth Muscle Cells Arterioscler. Thromb. Vasc. Biol., December 1, 1999; 19(12): 3025 - 3032. [Abstract] [Full Text] [PDF]

				A. M Dart and J. P.F Chin-Dusting Lipids and the endothelium Cardiovasc Res, August 1, 1999; 43(2): 308 - 322. [Abstract] [Full Text] [PDF]

				C. Banfi, L. Mussoni, P. Rise, M. G. Cattaneo, L. Vicentini, F. Battaini, C. Galli, and E. Tremoli Very Low Density Lipoprotein–Mediated Signal Transduction and Plasminogen Activator Inhibitor Type 1 in Cultured HepG2 Cells Circ. Res., July 23, 1999; 85(2): 208 - 217. [Abstract] [Full Text] [PDF]

				O. Johansen, I. Seljeflot, A. T. Hostmark, and H. Arnesen The Effect of Supplementation With Omega-3 Fatty Acids on Soluble Markers of Endothelial Function in Patients With Coronary Heart Disease Arterioscler. Thromb. Vasc. Biol., July 1, 1999; 19(7): 1681 - 1686. [Abstract] [Full Text] [PDF]

				L. Nilsson, T. Takemura, P. Eriksson, and A. Hamsten Effects of Fibrate Compounds on Expression of Plasminogen Activator Inhibitor-1 by Cultured Endothelial Cells Arterioscler. Thromb. Vasc. Biol., June 1, 1999; 19(6): 1577 - 1581. [Abstract] [Full Text] [PDF]

				A. Mavri, M. Stegnar, M. Krebs, J. T. Sentocnik, M. Geiger, and B. R. Binder Impact of Adipose Tissue on Plasma Plasminogen Activator Inhibitor-1 in Dieting Obese Women Arterioscler. Thromb. Vasc. Biol., June 1, 1999; 19(6): 1582 - 1587. [Abstract] [Full Text] [PDF]

				W. Dichtl, L. Nilsson, I. Goncalves, M. P. S. Ares, C. Banfi, F. Calara, A. Hamsten, P. Eriksson, and J. Nilsson Very Low-Density Lipoprotein Activates Nuclear Factor-{kappa}B in Endothelial Cells Circ. Res., May 14, 1999; 84(9): 1085 - 1094. [Abstract] [Full Text] [PDF]

				L. Nilsson, M. Gåfvels, L. Musakka, K. Ensler, D. K. Strickland, B. Angelin, A. Hamsten, and P. Eriksson VLDL activation of plasminogen activator inhibitor-1 (PAI-1) expression: involvement of the VLDL receptor J. Lipid Res., May 1, 1999; 40(5): 913 - 919. [Abstract] [Full Text]

				B. A. Allison, L. Nilsson, F. Karpe, A. Hamsten, and P. Eriksson Effects of Native, Triglyceride-Enriched, and Oxidatively Modified LDL on Plasminogen Activator Inhibitor-1 Expression in Human Endothelial Cells Arterioscler. Thromb. Vasc. Biol., May 1, 1999; 19(5): 1354 - 1360. [Abstract] [Full Text] [PDF]

				A. Festa, R. D'Agostino Jr, L. Mykkanen, R. Tracy, B. V. Howard, and S. M. Haffner Low-Density Lipoprotein Particle Size Is Inversely Related to Plasminogen Activator Inhibitor-1 Levels : The Insulin Resistance Atherosclerosis Study Arterioscler. Thromb. Vasc. Biol., March 1, 1999; 19(3): 605 - 610. [Abstract] [Full Text] [PDF]

				L. Nilsson, C. Banfi, U. Diczfalusy, E. Tremoli, A. Hamsten, and P. Eriksson Unsaturated Fatty Acids Increase Plasminogen Activator Inhibitor-1 Expression in Endothelial Cells Arterioscler. Thromb. Vasc. Biol., November 1, 1998; 18(11): 1679 - 1685. [Abstract] [Full Text] [PDF]

				H. E. Grenett, R. L. Benza, G. M. Fless, X.-N. Li, G. C. Davis, and F. M. Booyse Genotype-Specific Transcriptional Regulation of PAI-1 Gene by Insulin, Hypertriglyceridemic VLDL, and Lp(a) in Transfected, Cultured Human Endothelial Cells Arterioscler. Thromb. Vasc. Biol., November 1, 1998; 18(11): 1803 - 1809. [Abstract] [Full Text] [PDF]

				A. Geppert, S. Graf, R. Beckmann, S. Hornykewycz, E. Schuster, B. R. Binder, and K. Huber Concentration of Endogenous tPA Antigen in Coronary Artery Disease : Relation to Thrombotic Events, Aspirin Treatment, Hyperlipidemia, and Multivessel Disease Arterioscler. Thromb. Vasc. Biol., October 1, 1998; 18(10): 1634 - 1642. [Abstract] [Full Text] [PDF]

				P. K Shah Role of inflammation and metalloproteinases in plaque disruption and thrombosis Vascular Medicine, August 1, 1998; 3(3): 199 - 206. [Abstract] [PDF]

				J. Zhang, S. Ren, D. Sun, and G. X. Shen Influence of Glycation on LDL-Induced Generation of Fibrinolytic Regulators in Vascular Endothelial Cells Arterioscler. Thromb. Vasc. Biol., July 1, 1998; 18(7): 1140 - 1148. [Abstract] [Full Text] [PDF]

				J. Björkegren, F. Karpe, S. Vitols, P. Tornvall, and A. Hamsten Transient triglyceridemia in healthy normolipidemic men increases cellular processing of large very low density lipoproteins by fibroblasts in vitro J. Lipid Res., February 1, 1998; 39(2): 423 - 437. [Abstract] [Full Text]

				L. Byberg, A. Siegbahn, L. Berglund, P. McKeigue, R. Reneland, and H. Lithell Plasminogen Activator Inhibitor-1 Activity Is Independently Related to Both Insulin Sensitivity and Serum Triglycerides in 70-Year-Old Men Arterioscler. Thromb. Vasc. Biol., February 1, 1998; 18(2): 258 - 264. [Abstract] [Full Text] [PDF]

				P. Eriksson, L. Nilsson, F. Karpe, and A. Hamsten Very-Low-Density Lipoprotein Response Element in the Promoter Region of the Human Plasminogen Activator Inhibitor-1 Gene Implicated in the Impaired Fibrinolysis of Hypertriglyceridemia Arterioscler. Thromb. Vasc. Biol., January 1, 1998; 18(1): 20 - 26. [Abstract] [Full Text] [PDF]

				G. K. Goode, S. Garcia, and A. M. Heagerty Dietary Supplementation With Marine Fish Oil Improves In Vitro Small Artery Endothelial Function in Hypercholesterolemic Patients : A Double-Blind Placebo-Controlled Study Circulation, November 4, 1997; 96(9): 2802 - 2807. [Abstract] [Full Text]

				Y. Hong, N. L. Pedersen, N. Egberg, and U. de Faire Moderate Genetic Influences on Plasma Levels of Plasminogen Activator Inhibitor-1 and Evidence of Genetic and Environmental Influences Shared by Plasminogen Activator Inhibitor-1, Triglycerides, and Body Mass Index Arterioscler. Thromb. Vasc. Biol., November 1, 1997; 17(11): 2776 - 2782. [Abstract] [Full Text]

				X.-N. Li, H. E. Grenett, R. L. Benza, S. Demissie, S. L. Brown, E. M. Tabengwa, S. H. Gianturco, W. A. Bradley, G. M. Fless, and F. M. Booyse Genotype-Specific Transcriptional Regulation of PAI-1 Expression by Hypertriglyceridemic VLDL and Lp(a) in Cultured Human Endothelial Cells Arterioscler. Thromb. Vasc. Biol., November 1, 1997; 17(11): 3215 - 3223. [Abstract] [Full Text]

				M. Cigolini, G. Targher, I.A. B. Andreis, M. Tonoli, G. Agostino, and G. De Sandre Visceral Fat Accumulation and Its Relation to Plasma Hemostatic Factors in Healthy Men Arterioscler. Thromb. Vasc. Biol., March 1, 1996; 16(3): 368 - 374. [Abstract] [Full Text]

				D. Zitoun, L. Bara, A. Basdevant, and M. M. Samama Levels of Factor VIIc Associated With Decreased Tissue Factor Pathway Inhibitor and Increased Plasminogen Activator Inhibitor-1 in Dyslipidemias Arterioscler. Thromb. Vasc. Biol., January 1, 1996; 16(1): 77 - 81. [Abstract] [Full Text]

				F. Lopez-Segura, F. Velasco, J. Lopez-Miranda, P. Castro, R. Lopez-Pedrera, A. Blanco, J. Jimenez-Pereperez, A. Torres, J. Trujillo, J.M. Ordovas, et al. Monounsaturated Fatty Acid–Enriched Diet Decreases Plasma Plasminogen Activator Inhibitor Type 1 Arterioscler. Thromb. Vasc. Biol., January 1, 1996; 16(1): 82 - 88. [Abstract] [Full Text]

				L. Sironi, L. Mussoni, L. Prati, D. Baldassarre, M. Camera, C. Banfi, and E. Tremoli Plasminogen Activator Inhibitor Type-1 Synthesis and mRNA Expression in HepG2 Cells Are Regulated by VLDL Arterioscler. Thromb. Vasc. Biol., January 1, 1996; 16(1): 89 - 96. [Abstract] [Full Text]

				O. C. E. Gebara, M. A. Mittleman, P. Sutherland, I. Lipinska, T. Matheney, P. Xu, F. K. Welty, P. W. F. Wilson, D. Levy, J. E. Muller, et al. Association Between Increased Estrogen Status and Increased Fibrinolytic Potential in the Framingham Offspring Study Circulation, April 1, 1995; 91(7): 1952 - 1958. [Abstract] [Full Text]

				G. N. Levine, J. F. Keaney, and J. A. Vita Cholesterol Reduction in Cardiovascular Disease -- Clinical Benefits and Possible Mechanisms N. Engl. J. Med., February 23, 1995; 332(8): 512 - 521. [Full Text] [PDF]

				A. Hamsten Myocardial infarction at a young age: mechanisms and management Vascular Medicine, March 1, 1991; 2(1): 45 - 60. [PDF]